Lentiviral vectors are the carrier of choice for allogenic or autologous cell therapies (such as CAR-T) because of its capacity to permanently integrate viral genome into host cell DNA. To produce those vectors, cell therapy producers generally use a transient transfection system that is scaled-up during process development phases. FectoVIR®-LV is the next generation of transfection reagent, free of animal component, designed to improve LV productivity in HEK-293 cell systems. FectoVIR®-LV is made for large scale manufacturing with reduced complexation volume and increased complex stability. On top of the performance in titers and the scalability, FectoVIR®-LV is also compatible with standard expression booster such as sodium butyrate. These key benefits make FectoVIR®-LV transfection reagent a perfect match for lentiviral vector manufacturing.